Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 11, 2009

View Archived Issues

AIPL1 gene therapy shows promise for retinal dystrophies / News in Context

Alnylam and Tekmira enter research collaboration for systemic delivery of RNAi therapeutics

FDA places Repros' INDs for Proellex on clinical hold for safety reasons

Eden and Omnio sign agreement for production of protein candidate for wound healing

GSK to acquire Nabi's PentaStaph pentavalent S. aureus vaccine

Nanotherapeutics updates clinical progress of NanoBUP and NanoDOX

Antisoma to discontinue development of AS-1402 for breast cancer

European Commission grants orphan drug designation to Alexion's Soliris in aHUS

High interpatient variability of sildenafil exposure in neonates with PHT

Escitalopram treatment reduces benzodiazepine withdrawal symptoms

BLX-155 shows thrombolytic efficacy in porcine model of arteriovenous graft failure

Solulin restores cerebral blood flow and reduces infarct size in thrombotic stroke model

Diannexin exhibits potent in vitro and in vivo antithrombotic effects

PharmaMar reports discovery of natural compounds for cancer treatment

AstraZeneca claims novel AR ligands for the treatment of prostate cancer

Banyu presents glucokinase activators for the treatment of diabetes and obesity

Avila Therapeutics discloses new protease inhibitors for hepatitis C virus infection

Lilly discovers new MR antagonists for chronic kidney disease therapy

Curis and Debiopharm enter license agreement for CUDC-305 and Hsp90 technology

Spectrum acquires full rights and intellectual property to Altair's RenaZorb in all fields

ViroPharma initiates dosing in phase I trial of nontoxigenic C. difficile

Hisamitsu reports results from phase II study of HOB-294 in overactive bladder

Sepracor submits NDS to Health Canada for Stedesa as adjunctive therapy for epilepsy

FDA advisory committee to meet in September 2009 to review Allos' NDA for pralatrexate

FDA approves new formulation of Actelion's Ventavis for PAH

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...